Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023

Rhea-AI Summary

Revolution Medicines, Inc. (Nasdaq: RVMD) announced it will report its fourth quarter and full year 2022 financial results on February 27, 2023, after market close. Senior management will discuss these results and corporate progress during a webcast at 4:30 p.m. Eastern Time. The company is focused on developing targeted therapies for RAS-addicted cancers, with key products in clinical development, including RMC-6236 and RMC-6291. The webcast will also be available as an archived session on its website for at least 14 days.

Positive

• Focus on targeted therapies for RAS-addicted cancers.
• R&D pipeline includes multiple RAS(ON) Inhibitors in clinical development.

Negative

• None.

REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2022 on Monday, February 27, 2023, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress.

To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.

About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RAS^MULTI) and RMC-6291 (KRAS^G12C) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805 (KRAS^G12D) and RMC-0708 (KRAS^Q61H), both of which are currently in IND-enabling development, RMC-8839 (KRAS^G13C), and additional compounds targeting other RAS variants. RAS Companion Inhibitors currently in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

FAQ

When will Revolution Medicines report its financial results for 2022?

Revolution Medicines will report its financial results on February 27, 2023.

What time is the webcast for Revolution Medicines' financial results?

The webcast will be at 4:30 p.m. Eastern Time on February 27, 2023.

Where can I access the archived webcast of Revolution Medicines' financial results?

The archived webcast will be available on Revolution Medicines' website for at least 14 days after the live event.

What are the key products in Revolution Medicines' R&D pipeline?

Key products include RMC-6236 and RMC-6291, both in clinical development.

What is Revolution Medicines focused on?

The company is focused on developing novel targeted therapies for RAS-addicted cancers.